

ORAL PRESENTATION

Open Access

Dynamics of *P. vivax* clones in a cohort of children with or without primaquine treatment at baseline

Rahel Wampfler^{1,2*}, Leanne Robinson^{3,4}, Natalie Hofmann^{1,2}, Andreea Waltmann^{3,5}, Inoni Betuela⁴, Mariabeth Silkey^{1,2}, Peter Siba⁴, Tom Smith^{1,2}, Ivo Mueller^{3,6}, Ingrid Felger^{1,2}

From Challenges in malaria research: Core science and innovation
Oxford, UK. 22-24 September 2014

P. vivax was detected by PCR in 45% of children aged 5–10 years from our study area in Papua New Guinea (PNG). 504 children were randomized into 2 arms according to Primaquine (PQ) treatment or not at baseline and actively and passively followed for 9 months. We genotyped all *P. vivax* infections, the majority of these being multi-clone infections. All blood samples positive for *P. vivax* by qPCR were tested for gametocyte carriage by targeting *pvs25* transcripts. Primaquine reduced the risk of *P. vivax* infections by 80%. The multiplicity of infection and the density of asexual *P. vivax* stages were not significantly different in both treatment arms. The number of new clones (force of blood-stage infection) was 2.38 ± 0.17 per person per year-at-risk in the PQ-arm compared to 8.04 ± 0.41 in the Placebo arm ($P < 0.05$). The duration of infections did not differ between the treatment arms, with 73 days [95% CI: 33–849] and 68 days [95% CI: 40–247] in the PQ or Placebo arm, respectively. Detectability of *P. vivax* clones was low with 0.26 ± 0.06 and 0.24 ± 0.04 in the PQ and Placebo arms. PQ-treated children had a 75% lower risk of carrying gametocytes compared to Placebo recipients. *P. vivax* positive children in both arms were equally likely to show gametocyte positivity. We conclude that *P. vivax* relapses contribute significantly to the high burden of *P. vivax* infection and transmission in PNG. All other infection dynamics parameters were consistent between treatment arms and apparent relapses behave like new infections.

Authors' details

¹Swiss Tropical and Public Health Institute, Basel, Switzerland. ²University of Basel, Basel, Switzerland. ³Walter and Eliza Hall Institute, Parkville, Australia.
⁴PNG Institute of Medical Research, Madang & Maprik, Papua New Guinea.

¹Swiss Tropical and Public Health Institute, Basel, Switzerland
Full list of author information is available at the end of the article

⁵Department of Medical Biology, University of Melbourne, Victoria, Australia.

⁶Centre de Recerca en Salut Internacional de Barcelona (CRESIB), Barcelona, Spain.

Published: 22 September 2014

doi:10.1186/1475-2875-13-S1-O24

Cite this article as: Wampfler et al.: Dynamics of *P. vivax* clones in a cohort of children with or without primaquine treatment at baseline. *Malaria Journal* 2014 13(Suppl 1):O24.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

